BR112020010799A2 - proteínas vp1 modificadas de norovírus e vlps que compreendem proteínas vp1 modificadas de norovírus - Google Patents

proteínas vp1 modificadas de norovírus e vlps que compreendem proteínas vp1 modificadas de norovírus Download PDF

Info

Publication number
BR112020010799A2
BR112020010799A2 BR112020010799-9A BR112020010799A BR112020010799A2 BR 112020010799 A2 BR112020010799 A2 BR 112020010799A2 BR 112020010799 A BR112020010799 A BR 112020010799A BR 112020010799 A2 BR112020010799 A2 BR 112020010799A2
Authority
BR
Brazil
Prior art keywords
gii
norovirus
seq
plant
protein
Prior art date
Application number
BR112020010799-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Pierre-Olivier Lavoie
Marc-Andre D'Aoust
Original Assignee
Medicago Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc. filed Critical Medicago Inc.
Publication of BR112020010799A2 publication Critical patent/BR112020010799A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
BR112020010799-9A 2017-11-30 2018-11-30 proteínas vp1 modificadas de norovírus e vlps que compreendem proteínas vp1 modificadas de norovírus BR112020010799A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762593006P 2017-11-30 2017-11-30
US62/593,006 2017-11-30
US201862712744P 2018-07-31 2018-07-31
US62/712,744 2018-07-31
PCT/CA2018/051530 WO2019104439A1 (en) 2017-11-30 2018-11-30 Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins

Publications (1)

Publication Number Publication Date
BR112020010799A2 true BR112020010799A2 (pt) 2020-11-10

Family

ID=66663733

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020010799-9A BR112020010799A2 (pt) 2017-11-30 2018-11-30 proteínas vp1 modificadas de norovírus e vlps que compreendem proteínas vp1 modificadas de norovírus

Country Status (15)

Country Link
US (2) US11602558B2 (https=)
EP (1) EP3717648A4 (https=)
JP (2) JP7579143B2 (https=)
KR (1) KR102878449B1 (https=)
CN (1) CN111727255A (https=)
AU (1) AU2018375695B2 (https=)
BR (1) BR112020010799A2 (https=)
CA (1) CA3083857A1 (https=)
IL (1) IL274736A (https=)
MX (1) MX2020005530A (https=)
PH (1) PH12020550732A1 (https=)
RU (1) RU2020116307A (https=)
SG (1) SG11202004668WA (https=)
WO (1) WO2019104439A1 (https=)
ZA (2) ZA202003831B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7420339B2 (ja) * 2019-10-11 2024-01-23 学校法人北里研究所 変異ノロウイルス粒子とその生産方法
WO2022081870A1 (en) * 2020-10-14 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized norovirus virus-like particles as vaccine immunogens
CN113481328B (zh) * 2021-07-23 2023-10-27 中国科学院微生物研究所 用于检测临床样本中gi.5型诺如病毒的试剂盒及专用引物
EP4422681A4 (en) * 2021-10-27 2025-11-19 Univ Pennsylvania VACCINE AGAINST A NOROVIRUS AND METHODS OF USE
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant
WO2025077799A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Method of preparing norovirus vaccine without adjuvant
CN118126202B (zh) * 2024-05-07 2024-07-30 上海瑞宙生物科技有限公司 一种诺如病毒类病毒颗粒及其应用
CN118773218B (zh) * 2024-08-22 2025-09-30 中国医学科学院医学生物学研究所 一种诺如病毒gii.17型病毒样颗粒及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
SG10202012986SA (en) 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
AU2009279456B2 (en) * 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
PH12012500565B1 (en) * 2009-09-22 2018-01-12 Medicago Inc Method of preparing plant-derived proteins
AU2011276328C1 (en) 2010-07-06 2016-01-21 Novartis Ag Norovirus derived immunogenic compositions and methods
EP2956169B1 (en) * 2013-02-12 2018-04-11 THE UNITED STATES OF AMERICA, represented by the S Monoclonal antibodies that neutralize norovirus
US9975923B2 (en) 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
EP3583950A1 (en) * 2013-05-09 2019-12-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
JP5963811B2 (ja) 2014-07-18 2016-08-03 オリンパス株式会社 治療用超音波振動子
EP3037386A1 (en) 2014-12-23 2016-06-29 Casale SA A plant and a process for ammonia production with cryogenic purification, and a related method of revamping
WO2016200951A1 (en) * 2015-06-12 2016-12-15 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
EP4631970A3 (en) * 2016-05-04 2026-01-07 CureVac SE Nucleic acid molecules and uses thereof
EP3601580A4 (en) 2017-03-23 2021-01-06 Medicago Inc. NOROVIRUS FUSION PROTEINS AND VLPS WITH NOROVIRUS FUSION PROTEINS

Also Published As

Publication number Publication date
PH12020550732A1 (en) 2021-04-19
SG11202004668WA (en) 2020-06-29
EP3717648A4 (en) 2021-12-01
WO2019104439A1 (en) 2019-06-06
KR102878449B1 (ko) 2025-10-30
AU2018375695A1 (en) 2020-06-11
KR20200092363A (ko) 2020-08-03
US20200330583A1 (en) 2020-10-22
EP3717648A1 (en) 2020-10-07
ZA202003831B (en) 2023-10-25
JP2024109835A (ja) 2024-08-14
US12076388B2 (en) 2024-09-03
CN111727255A (zh) 2020-09-29
US11602558B2 (en) 2023-03-14
IL274736A (en) 2020-07-30
JP2021503962A (ja) 2021-02-15
CA3083857A1 (en) 2019-06-06
US20230293663A1 (en) 2023-09-21
AU2018375695B2 (en) 2025-01-02
RU2020116307A (ru) 2021-12-30
JP7579143B2 (ja) 2024-11-07
MX2020005530A (es) 2021-01-15
ZA202306500B (en) 2024-10-30

Similar Documents

Publication Publication Date Title
US12076388B2 (en) Modified norovirus VP1 proteins and VLPS comprising modified norovirus VP1 proteins
US11987601B2 (en) Norovirus fusion proteins and VLPs comprising norovirus fusion proteins
JP6297488B2 (ja) 植物中での狂犬病ウイルス様粒子の生成
KR102162118B1 (ko) 식물에서 로타바이러스-유사 입자 생산
TW202017937A (zh) 流感病毒血球凝集素突變體
WO2005032457A2 (en) Vectors and methods for immunization against norwalk virus using transgenic plants
JP2022521217A (ja) ロタウイルスｖｐ７融合タンパク質およびそれらを含むロタウイルス様粒子
JP7429684B6 (ja) 改変ノロウイルスｖｐ１タンパク質および改変ノロウイルスｖｐ１タンパク質を含むｖｌｐ
WO2016115630A1 (en) Rotavirus-like particle production in plants
TW202018084A (zh) 修飾之諾羅病毒vp1蛋白及包含修飾之諾羅病毒vp1蛋白之vlp
WO2023049983A1 (en) Cpmv vlps displaying sars-cov-2 epitopes
MX2015002835A (es) Produccion de particulas similares a picornavirus en plantas.
KR20250053121A (ko) 변형된 인플루엔자 b 바이러스 헤마글루티닌

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements